[{"data":1,"prerenderedAt":227},["ShallowReactive",2],{"drug-lisdexamfetamine":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":21,"regimens":84,"contraindications":112,"warnings":122,"renal":130,"monitoring":131,"interactions":132,"review":133,"examples":136,"atc":140,"iran":142,"usApproval":170,"links":176,"populations":192},"lisdexamfetamine",1,{"fa":7,"en":8},"لیزدگزامفتامین","Lisdexamfetamine","nervous-system",{"fa":11,"en":12},"محرک CNS (آمفتامین)","CNS stimulant (amphetamine)",[14],{"name":15,"market":16},"Vyvanse","US",[18,19,20,7],"vyvanse","elvanse","ویوانس",[22,36,44,52,60,68,76],{"id":23,"form":24,"route":25,"label":26,"concentration":27,"markets":31,"refs":32},"cap-10","capsule","oral","10 mg capsule",{"amount":28,"unit":29,"perUnit":24,"scored":30},10,"mg",false,[16],[33],{"source":34,"section":35},"fda-vyvanse","3",{"id":37,"form":24,"route":25,"label":38,"concentration":39,"markets":41,"refs":42},"cap-20","20 mg capsule",{"amount":40,"unit":29,"perUnit":24,"scored":30},20,[16],[43],{"source":34,"section":35},{"id":45,"form":24,"route":25,"label":46,"concentration":47,"markets":49,"refs":50},"cap-30","30 mg capsule",{"amount":48,"unit":29,"perUnit":24,"scored":30},30,[16],[51],{"source":34,"section":35},{"id":53,"form":24,"route":25,"label":54,"concentration":55,"markets":57,"refs":58},"cap-40","40 mg capsule",{"amount":56,"unit":29,"perUnit":24,"scored":30},40,[16],[59],{"source":34,"section":35},{"id":61,"form":24,"route":25,"label":62,"concentration":63,"markets":65,"refs":66},"cap-50","50 mg capsule",{"amount":64,"unit":29,"perUnit":24,"scored":30},50,[16],[67],{"source":34,"section":35},{"id":69,"form":24,"route":25,"label":70,"concentration":71,"markets":73,"refs":74},"cap-60","60 mg capsule",{"amount":72,"unit":29,"perUnit":24,"scored":30},60,[16],[75],{"source":34,"section":35},{"id":77,"form":24,"route":25,"label":78,"concentration":79,"markets":81,"refs":82},"cap-70","70 mg capsule",{"amount":80,"unit":29,"perUnit":24,"scored":30},70,[16],[83],{"source":34,"section":35},[85],{"id":86,"disease":86,"label":87,"population":90,"type":94,"unit":29,"dose":95,"refs":98,"notes":101},"adhd",{"fa":88,"en":89},"ADHD — ۶ سال به بالا: شروع ۳۰ mg صبح‌ها (تا ۷۰ mg)","ADHD — ≥6 y: start 30 mg every morning (up to 70 mg)",{"minAge":91},{"value":92,"unit":93},6,"year","titration",{"dividedDoses":5,"titration":96},{"start":48,"increment":28,"incrementEveryDays":97,"max":80},7,[99],{"source":34,"section":100},"2.3",[102],{"text":103,"refs":106},{"fa":104,"en":105},"افزایش ۱۰ یا ۲۰ mg تقریباً هفتگی. صبح؛ دوز بعدازظهر نه (بی‌خوابی). نارسایی شدید کلیه: حداکثر ۵۰ mg؛ ESRD: ۳۰ mg.","Increase by 10 or 20 mg about weekly. Morning; avoid afternoon doses (insomnia). Severe renal impairment: max 50 mg; ESRD: 30 mg.",[107,108,110],{"source":34,"section":100},{"source":34,"section":109},"2.2",{"source":34,"section":111},"2.5",[113],{"id":114,"severity":115,"text":116,"refs":119},"ci","block",{"fa":117,"en":118},"حساسیت به آمفتامین‌ها؛ MAOI همزمان یا ظرف ۱۴ روز (از جمله لینزولید یا متیلن بلو وریدی).","Hypersensitivity to amphetamines; MAOIs now or within 14 days (including linezolid or IV methylene blue).",[120],{"source":34,"section":121},"4",[123],{"text":124,"refs":127},{"fa":125,"en":126},"هشدار جعبه‌ای: سوءمصرف، مصرف نادرست و اعتیاد؛ پیش از تجویز خطر بررسی و در طول درمان پایش شود.","Boxed warning: abuse, misuse and addiction; assess risk before prescribing and monitor during treatment.",[128],{"source":34,"section":129},"Boxed Warning",[],[],[],{"status":134,"reviewer":135,"date":135},"unverified",null,[137],{"regimen":86,"formulation":45,"input":138,"expect":139},{"ageYears":28,"weightKg":48},{"perDose":48,"tabletsPerDoseRounded":5},[141],"N06BA12",{"status":143,"forms":144,"refs":165},"registered",[145,149,153,157,161],{"code":146,"en":147,"fa":148},"52326","LISDEXAMFETAMINE 70 MG CAP","کپسول لیزدگزامفتامین ۷۰ میلی‌گرم",{"code":150,"en":151,"fa":152},"52324","LISDEXAMFETAMINE 50 MG CAP","کپسول لیزدگزامفتامین ۵۰ میلی‌گرم",{"code":154,"en":155,"fa":156},"52322","LISDEXAMFETAMINE 30 MG CAP","کپسول لیزدگزامفتامین ۳۰ میلی‌گرم",{"code":158,"en":159,"fa":160},"52320","LISDEXAMFETAMINE 10 MG CAP","کپسول لیزدگزامفتامین ۱۰ میلی‌گرم",{"code":162,"en":163,"fa":164},"52321","LISDEXAMFETAMINE 20 MG CAP","کپسول لیزدگزامفتامین ۲۰ میلی‌گرم",[166],{"source":167,"section":168,"url":169},"darooyab-generic","G-4794\u002FLisdexamfetamine","https:\u002F\u002Fwww.darooyab.ir\u002FG-4794\u002FLisdexamfetamine",{"kind":171,"refs":172,"id":175},"NDA",[173],{"source":34,"section":174},"SPL approval \u002F marketing category","NDA021977",[177,180,184,187,190],{"kind":178,"url":179,"label":175},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=021977",{"kind":181,"url":182,"label":183},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=704e4378-ca83-445c-8b45-3cfa51c1ecad","FDA Vyvanse",{"kind":185,"url":186,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa607047.html",{"kind":188,"url":189,"label":141},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=N06BA12",{"kind":191,"url":169,"label":8},"darooyab",{"pregnancy":193,"lactation":202,"pediatric":211,"geriatric":219},{"level":194,"text":195,"quote":198,"refs":199},"caution",{"fa":196,"en":197},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary The limited available data from published literature and postmarketing reports on use of VYVANSE in pregnant women are not sufficient to inform a drug-associated risk for major birth defects and miscarriage.",[200],{"source":34,"section":201},"8.1",{"level":203,"text":204,"quote":207,"refs":208},"avoid",{"fa":205,"en":206},"برچسب: شیردهی توصیه نمی‌شود یا باید بین دارو و شیردهی یکی انتخاب شود.","Label: breastfeeding not recommended, or choose between the drug and breastfeeding.","… tions, blood pressure and heart rate increase, suppression of growth, and peripheral vasculopathy, advise patients that breastfeeding is not recommended during treatment with VYVANSE.",[209],{"source":34,"section":210},"8.2",{"level":194,"text":212,"quote":215,"refs":216},{"fa":213,"en":214},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","ADHD Safety and effectiveness of VYVANSE have been established in pediatric patients with ADHD ages 6 to 17 years [see Dosage and Administration (2.3) , Adverse Reactions (6.1) , Clinical Pharmacology (12.3) , and Clinical Studies (14.1) ] .",[217],{"source":34,"section":218},"8.4",{"level":194,"text":220,"quote":223,"refs":224},{"fa":221,"en":222},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","In general, dose selection for an elderly patient should start at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.",[225],{"source":34,"section":226},"8.5",1792115186447]